Brief: Bioarctic Receives Orphan Drug Designation For Exidavnemab In The US
17/03/2025 17:27
March 17 (Reuters) - BioArctic AB BIOAb.ST: BIOARCTIC RECEIVES ORPHAN DRUG DESIGNATION FOR EXIDAVNEMAB THE US Source text: ID:nWkr9LStpD Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln